Lithium level and inter-episode symptoms in affective disorder

Area of Science:

• Psychiatry
• Pharmacology
• Neuroscience

Background:

• Lithium is a common mood stabilizer for affective disorders.
• Maintaining optimal lithium levels is crucial for treatment efficacy.
• Inter-episode symptoms can impact quality of life for patients with affective disorder.

Purpose of the Study:

• To investigate the relationship between plasma lithium levels and inter-episode symptoms in patients with affective disorder.
• To determine if higher lithium levels correlate with reduced symptom severity or frequency between mood episodes.

Main Methods:

• A prospective 1-year study was conducted with 42 patients on lithium prophylaxis alone.
• Patients were divided into two groups based on mean plasma lithium levels (above or below the median).
• Inter-episode symptoms, mood shifts, and subclinical symptoms (General Behavior Inventory) were assessed.

Main Results:

• Significant differences in mean plasma lithium levels were observed between groups (0.82 +/- 0.10 mEq/l vs. 0.52 +/- 0.09 mEq/l).
• No significant differences were found in the incidence of major symptoms, mood shifts, or subclinical symptoms between the high and low lithium level groups.
• This suggests that lithium levels above the median did not offer additional clinical benefits regarding inter-episode symptom control.

Conclusions:

• Plasma lithium levels within the studied range may not significantly impact the frequency or severity of inter-episode symptoms in affective disorder.
• Further research is needed to explore other factors influencing inter-episode symptomology and to define optimal lithium targets.
• These findings challenge the assumption that maximizing lithium levels always leads to better symptom control in the inter-episode phase.